Emergent lineages of mumps virus suggest the need for a polyvalent vaccine

May, Meghan; Rieder, Courtney A.; Rowe, Rebecca J.

doi:10.1016/j.ijid.2017.09.024

Cited by 39 publications

(36 citation statements)

References 31 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…It has been found that the efficacy of the mumps vaccine containing the Jeryl Lynn strain was 95-96% [90]. The effectiveness of two doses of MMR immunization is not as high as expected, and outbreaks have been reported in countries with high vaccine coverage [91][92][93]. It was reported that the estimated vaccine effectiveness for one-dose MMR vaccination was 85.4% (95% CI: 67.3-93.4%), and that for two-dose MMR vaccination was 88.5% (95% CI: 78.1-93.9%) in a study in Spain [94].…”

Section: Jeryl Lynn Strain Mumps Vaccinementioning

confidence: 99%

Current Status of Mumps Virus Infection: Epidemiology, Pathogenesis, and Vaccine

Chang²,

Chen

2020

IJERPH

View full text Add to dashboard Cite

Mumps is an important childhood infectious disease caused by mumps virus (MuV). We reviewed the epidemiology, pathogenesis, and vaccine development of mumps. Previous studies were identified using the key words “mumps” and “epidemiology”, “pathogenesis” or “vaccine” in MEDLINE, PubMed, Embase, Web of Science, and Google Scholar. We excluded the articles that were not published in the English language, manuscripts without abstracts, and opinion articles from the review. The number of cases caused by MuV decreased steeply after the introduction of the mumps vaccine worldwide. In recent years, a global resurgence of mumps cases in developed countries and cases of aseptic meningitis caused by some mumps vaccine strains have renewed the importance of MuV infection worldwide. The performance of mumps vaccination has become an important issue for controlling mumps infections. Vaccine development and routine vaccination are still effective measures to globally reduce the incidence of mumps infections. During outbreaks, a third of MMR vaccine is recommended for groups of persons determined by public authorities.

show abstract

Section: Jeryl Lynn Strain Mumps Vaccinementioning

confidence: 99%

Current Status of Mumps Virus Infection: Epidemiology, Pathogenesis, and Vaccine

Chang²,

Chen

2020

IJERPH

View full text Add to dashboard Cite

show abstract

“…lack of a durable T-cell mediated response, as well as antigenic differences between vaccine and circulating mumps strains, (1,4,(7)(8)(9)(10)(21)(22)(23)(24). As such, the mismatch between vaccine and circulating mumps stains has also prompted the consideration of a polyvalent vaccine (1,25) In our study, most of the samples submitted for MuV testing were CSF and blood specimens. However, information on the clinical presentation of the patients from whom specimens were collected was not Our finding of a male predominance with regards to infections is similar to what has been reported in other studies (26,27).…”

Section: Operational Definitionsmentioning

confidence: 97%

Epidemiology of laboratory-confirmed mumps infections in South Africa, 2012-2017: a cross-sectional study

Sikhosana

Kuonza

Motaze

2020

Preprint

View full text Add to dashboard Cite

Background Data on the burden of mumps in South Africa are limited and the epidemiology of mumps in this setting is not well understood. We present findings of analysis of mumps data in South Africa from 2012 to 2017. Methods This cross-sectional study included secondary data on laboratory-confirmed mumps infections from 2012 to 2017, archived at the South African National Health Laboratory Services’ data repository as well as from four private laboratories. Mumps-specific immunoglobulin M (IgM) and/or viral nucleic acid positive results represented acute infections. We used age-specific mid-year population estimates for each study year as denominators when calculating annual incidence. We calculated seasonality indices to determine seasonality of mumps infections. Results Out of 48580 records obtained from the public and private sectors, 46713 (96.2%) were from the private sector. Over the study period, there were 7494 acute infections, 7085 (94.5%) of which were recorded in the private sector. Of these 7494 infections, 3924 (52.4%) occurred in males. The proportion of samples tested that were IgM positive was 18.6% (1058/5682) in 2012, 15% (1016/6790) in 2013, 15.8% (1280/8093) in 2014, 15.5% (1384/8944) in 2015, 13.1% (1260/9629) in 2016 and 15.8% (1496/9442) in 2017. The cumulative incidence rate per 100000 was highest in children between one and nine years throughout the study period. Infections tended to peak in the October-November months, which represents spring in our setting. Most infections occurred in Gauteng, Western Cape and KwaZulu-Natal and this was consistent throughout the study period. Conclusion Mumps infections predominantly occurred in spring, affecting children below 10 years of age and individuals who were male. There were fewer tests performed in the public sector compared to the private sector. Since only laboratory data was analysed our results represent and underestimate of disease burden. Further studies that include clinical data are required to provide better estimates of disease burden in South Africa.

show abstract

“…Besides these more obvious antigenic changes, resulting in serotype replacements, less-well defined and more diffuse antigenic changes may also change the effectiveness of particular vaccines. This is illustrated by the reemergence of mumps in highly vaccinated populations, indicating waning of the vaccine-acquired immune response and reduced capability to protect against antigenically divergent strains [128,129].…”

Section: Evolution Of the Pathogensmentioning

confidence: 99%

Immune surveillance for vaccine-preventable diseases

Hartog

Binnendijk

Buisman

et al. 2020

Expert Review of Vaccines

View full text Add to dashboard Cite

Introduction: Immunesurveillance is an important tool to monitor the protection of the population against vaccine-preventable diseases, which is currently mostly based on the detection of specific serum antibodies. However, the landscape of immune surveillance is changing, driven by emerging and evolving pathogens, changes in the age distribution of the population and scientific understanding of protective immunity, necessitating a comprehensive review. Areas covered: To anticipate these changes, reliable and high-throughput detection of antibody levels is desired to enable screening in larger population settings. Antibody levels alone do not always equate with protection and may require additional functional testing of the antibodies or immune cell-based assays. In addition, the location (systemic or locally mucosal) of the infection and whether the antibodies are induced through infection or vaccination have implications for both immune protection and assessing immune status. Expert commentary: In order to perform multicenter studies on many samples for multiple antigens, more validated reference materials and wider adoption of high-throughput techniques are needed. The field of serosurveillance will also benefit from better correlates of protection and understanding of (local) mechanisms of protection. Here we give an overview of the current state-of-the-art of serosurveillance and how the field could move forward. ARTICLE HISTORY

show abstract

Emergent lineages of mumps virus suggest the need for a polyvalent vaccine

Cited by 39 publications

References 31 publications

Current Status of Mumps Virus Infection: Epidemiology, Pathogenesis, and Vaccine

Current Status of Mumps Virus Infection: Epidemiology, Pathogenesis, and Vaccine

Epidemiology of laboratory-confirmed mumps infections in South Africa, 2012-2017: a cross-sectional study

Immune surveillance for vaccine-preventable diseases

Contact Info

Product

Resources

About